Research Article

Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy

Table 3

Sialylation pattern of E2 IgG antibodies in patients with a sustained virological response by HCV genotype.

HCV genotype ()SNA bindingSNA/IgG ratio

1b (24)
3a (37)
value0.090.02